Blake Badgett, MD
Family Medicine · Weatherford, OKNPI 1376636084
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 57.5% of the total. 2025 is the largest year on record at $2,713, more than ten times the $148 reported in 2019. Among family medicine clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 197 payments — averaging $36.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$4K
- AbbVie$593
- AstraZeneca$518
- Merck$420
- Pfizer$215
- Novo Nordisk$174
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$3,84854%
- Travel & lodging$1011%
- Food & beverage$3,11444%
- Education$891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 11 | $4,115 |
| AbbVie(2 entities) | 40 | $593 |
| AstraZeneca | 29 | $518 |
| Merck | 29 | $420 |
| Pfizer | 13 | $215 |
| Novo Nordisk | 10 | $174 |
| Bayer | 8 | $133 |
| GSK | 7 | $109 |
| Corcept Therapeutics | 2 | $98 |
| Eisai Inc. | 5 | $74 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Amgen | 5 | $64 |
| Radius Health, Inc. | 3 | $60 |
| Boehringer Ingelheim | 4 | $59 |
| Lilly USA, LLC | 4 | $55 |
| Novartis | 3 | $46 |
| Adlon Therapeutics L.p. | 3 | $43 |
| Edwards Lifesciences | 1 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Gilead | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Johnson & Johnson | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 1 | $27 |
| Organon | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Exeltis, USA Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$4,066
How this compares
$7,151 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 168 | $156,882 |
| EliquisApixaban | 276 | $135,659 |
| FarxigaDapagliflozin Propanediol | 145 | $123,978 |
| JanuviaSitagliptin Phosphate | 121 | $95,779 |
| JardianceEmpagliflozin | 77 | $63,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $37,113 |
| KerendiaFinerenone | 30 | $35,473 |
| TrulicityDulaglutide | 24 | $29,366 |
| XareltoRivaroxaban | 44 | $28,806 |
| MounjaroTirzepatide | 26 | $26,917 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $24,779 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $17,491 |
| MyrbetriqMirabegron | 32 | $16,962 |
| RybelsusSemaglutide | 13 | $12,555 |
| RytaryCarbidopa/Levodopa | 18 | $10,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $174 | $169,438181 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $518 | $148,756182 claims |
| PfizerEliquis | $215 | $135,659276 claims |
| MerckJanuvia, Janumet Xr | $420 | $113,270137 claims |
| Boehringer IngelheimJardiance, Tradjenta, Pradaxa | $59 | $72,097117 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $55 | $56,28250 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $109 | $48,41382 claims |
| BayerKerendia | $133 | $35,47330 claims |
| Johnson & JohnsonXarelto | $31 | $28,80644 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $20 | $10,53822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Weatherford
- Alexander FrankOklahoma City$3.1M
- Stanley ShadidEdmond$363K
- Geoffrey PlumleeTulsa$297K
- Curtis HarrisAda$125K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Lisa ConneryNorman$105K
- Michael RobinsonElk City$84K
- Kimberly HuttonTulsa$76K
- James BeebeMuskogee$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.